慢性リンパ性白血病
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.J Clin Oncol. 2019 Jun 1;37(16):1391-1402PMID: 30995176 doi: 10…
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 7;133(10):1011-1019 PMID: 30530801, DOI: 10.1182/blood-2018-10-879429 イブルチニブは,経口のブルトン型チロシンキナーゼ…
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyLancet Haema…
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.(Blood. 2017 Jun 29;129(26):3419-3427.) イブルチニブ(ibrutinib)で治療している慢性リンパ性白血病(CLL)患者の中で、早期に進行する患者はリヒター転換(Richter tra…
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. NEJM 2014, PMID 24881631 [背景] 慢性リンパ性白血病(CLL)と小リンパ球性リンパ腫(SLL)の患者において、治療への反応期間が短かいことや、特定の染色体異常が予後の悪さと関…
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia (Blood 2014;123:2783-2790) Richter sydrome (RS)は予後不良と関連している。組織学的にaggressiveな慢性リンパ性白血病(histolog…